PATENT CLAIM ANALYSIS

Application Number: 16293198
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["514", "379000"]

Abstract:
The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claim (Index 13):
The composition of  claim 11 , wherein said metabolite of bupropion is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, or a pharmaceutically acceptable salt or prodrug thereof.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 99.0
- Lexical Diversity: 1.16667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10440404', '10830071', '12205769', '10147588', '10150341']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.742443461190919
- 35 USC 102 Novelty (BERT): 0.5086312084748928
- Combined Prediction Score: 0.7190622359193164
- Mean Citation Score: 234.11792000000003
- Max Citation Score: 274.77307
- Similarity Product: 224.92450164364573

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test